← back to search

Gary E. Raskob

University of Oklahoma Health Sciences Center · US
Area of research
Internal Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, and Diagnosis and Treatment of Venous Diseases.
h-index
70
citations
28,747
works
255
NIH funding
primary concept
Medicine
email

Recent publications

Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model
Thrombosis and Haemostasis 2024cited by 11position: middledoi
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
European Heart Journal 2023cited by 72position: middledoi
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
The Oncologist 2023cited by 34position: middledoi
Abelacimab for Prevention of Venous Thromboembolism
New England Journal of Medicine 2021cited by 282position: middledoi
Milvexian for the Prevention of Venous Thromboembolism
New England Journal of Medicine 2021cited by 241position: lastdoi
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism
Annals of Internal Medicine 2021cited by 137position: middledoi
Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis
Journal of Thrombosis and Haemostasis 2021cited by 50position: middledoi
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients
Journal of the American Heart Association 2021cited by 43position: firstdoi
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
JAMA 2020cited by 246position: lastdoi
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Journal of the American College of Cardiology 2020cited by 63position: lastdoi
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study
Thrombosis Research 2019cited by 78position: lastdoi
Clinical implications of incidental venous thromboembolism in cancer patients
European Respiratory Journal 2019cited by 44position: middledoi
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
New England Journal of Medicine 2018cited by 245position: lastdoi
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study
Thrombosis and Haemostasis 2018cited by 213position: lastdoi
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Thrombosis and Haemostasis 2018cited by 34position: middledoi
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
New England Journal of Medicine 2017cited by 1,594position: firstdoi
Global public awareness about atrial fibrillation
Research and Practice in Thrombosis and Haemostasis 2017cited by 22position: middledoi
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
The Lancet Haematology 2016cited by 67position: firstdoi
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study
The Lancet Haematology 2016cited by 34position: middledoi
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
CHEST Journal 2016cited by 30position: middledoi
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs
Thrombosis Research 2015cited by 527position: lastdoi
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
Journal of Thrombosis and Haemostasis 2015cited by 196position: middledoi
Global public awareness of venous thromboembolism
Journal of Thrombosis and Haemostasis 2015cited by 146position: middledoi
Edoxaban for treatment of venous thromboembolism in patients with cancer
Thrombosis and Haemostasis 2015cited by 83position: middledoi
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
New England Journal of Medicine 2014cited by 617position: middledoi
Thrombosis: a major contributor to the global disease burden
Journal of Thrombosis and Haemostasis 2014cited by 476position: firstdoi
Thrombosis: A major contributor to global disease burden
Thrombosis Research 2014cited by 297position: firstdoi
Thrombosis: A Major Contributor to Global Disease Burden
Seminars in Thrombosis and Hemostasis 2014cited by 142position: middledoi
Clinical features of paediatric pulmonary hypertension: a registry study
The Lancet 2012cited by 510position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jeffrey I. Weitz · McMaster University Medical Centre21 papers (2014–2023)Harry R. Büller · Amsterdam University Medical Centers13 papers (2014–2023)Annelise Segers · University of Oklahoma Health Sciences Center10 papers (2014–2021)Peter Verhamme · Hospital Universitario La Paz10 papers (2014–2023)Michael Grosso · Daiichi Sankyo (United States)8 papers (2015–2024)Elaine M. Hylek · Boston University7 papers (2014–2021)Walter Ageno · Aziende Socio Sanitarie Territoriale dei Sette Laghi7 papers (2016–2021)Marc Carrier · University of Ottawa6 papers (2015–2023)Nick van Es · Pulmonary Hypertension Association6 papers (2015–2024)Ajay K. Kakkar · Thrombosis Research Institute5 papers (2015–2023)Marcello Di Nisio · University of Alabama at Birmingham5 papers (2017–2024)Pantep Angchaisuksiri · Mahidol University5 papers (2014–2017)Stavros Konstantinides · Agia Olga Hospital5 papers (2014–2017)Micah McCumber · University of Oklahoma Health Sciences Center5 papers (2014–2017) · 5 papers (2014–2017)Aaron M. Wendelboe · University of Oklahoma Health Sciences Center5 papers (2014–2017)George Zhang · Shihezi University4 papers (2016–2019)A. K. Kakkar · Banasthali University4 papers (2014–2019)Alexander Gallus · University of Oklahoma Health Sciences Center4 papers (2014–2015)Beverley J. Hunt · Guy's and St Thomas' NHS Foundation Trust4 papers (2014–2017)